# A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

> **NCT04457869** · PHASE2 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 43 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** F520

## Key facts

- **NCT ID:** NCT04457869
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2022-07-31
- **Final completion:** 2023-01-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457869, "A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04457869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*